Advances in the study of inhibitors of kinases and nuclear factors for treating allergic asthma

Currently, about 300 million people worldwide are affected by asthma.  Most of these sufferers inhale immunosuppressants (ie corticosteroids) and β-adrenergic receptor agonists for their asthma treatment.  However, about 5%−10% of patients of asthma have poor response to such treatment.  Investigation of kinase signaling pathway and nuclear transcription factor as a target molecule in the treatment of allergic asthma has been the concern of scholars home and abroad.  This paper reviewed inhibitors of kinase signaling pathway and nuclear transcription factors for the treatment of asthma.